Osteoarthritis is leads to the breakage of the joint cartilage and is one of the most common forms of arthritis. Osteoarthritis can cause immense pain, swelling, and a limited motion in affected joints. Usually, hands, knees, hips and the spine are highly probable to be affected by osteoarthritis. As per the report by Market Research Future (MRFR), the global osteoarthritis market is expected to ascend at a 6.8% CAGR through the forecast period.
Some factors, as mentioned in the latest report by Market Research Future (MRFR) contributing to the ascension of the global osteoarthritis market include a rising prevalence of the geriatric population across the globe. Further, unhealthy lifestyle has led to a proliferation in the number of overweight individuals, magnifying the risk of osteoarthritis among consumers. An improvement in detection techniques has led to a rise in detection rates, driving the global osteoarthritis market. Other than that, improved accessibility to healthcare facilities has also contributed to the global osteoarthritis market growth by 2023.
Get Free PDF Sample Copy of Report @ https://www.marketresearchfuture.com/sample_request/1609
The report has mentioned various players in the global Osteoarthritis therapeutics marketincluding Abbott. (U.S.), Novartis AG (Europe), Pfizer Inc. (U.S.), Eli Lilly and Company (U.S.), ABIOGEN PHARMA S.p.A (Europe), Merck Sharp & Dohme Corp. (U.S.), TissueGene Inc. (U.S.), Ampio Pharmaceuticals Inc. (U.S.), Regeneron (U.S.).
Industry Update
June 2019: A treatment developed by biomedical engineers in the Cornell University uses a synthetic version of a joint lubricant to bind the surface of cartilage in joints. It acts as a cushion during heavy activities such as running. This treatment is currently in canine clinical trials and will be eventually used in humans.
March 2019: Researchers from the Kennedy Institute of Rheumatology at the University of Oxford, and Jenner Institute have collaboratively developed a vaccine that could be used to treat chronic pain caused by osteoarthritis. The virus-like particle vaccine is capable of triggering the immune system to produce antibodies which would help to block naturally-occurring NGF and alleviate osteoarthritis pain.
Segmental Analysis
The global osteoarthritis market is studied for various segments based on type, diagnosis, treatment, end-users, and region. Based on type, the global osteoarthritis market is segmented into hip osteoarthritis, wrist osteoarthritis, and spinal osteoarthritis. Based on end-user, the osteoarthritis market is segmented into research organization, medical institutes, and hospitals & clinics.
Based on diagnosis, the global osteoarthritis market is segmented into imaging, and joint fluid analysis. Among these segments, the imaging segment is further sub-segmented into X-rays, and magnetic resonance imaging (MRI).
Based on treatment, the osteoarthritis market is segmented into medication, surgery, and therapy. The medication segment is further sub-segmented into non-steroidal anti-inflammatory drugs and analgenics. The analgenics segment is further segmented into acetaminophen and duloxetine. The non-steroidal anti-inflammatory drugs segment is further sub-segmented into ibuprofen, aspirin, naproxen, and naproxen sodium.
Regional Analysis of Global Osteoarthritis Market
The global osteoarthritis market is segmented into the Americas, Europe, Asia Pacific, and the Middle East & Africa. Among these segments, the Americas are expected to spearhead the global osteoarthritis market over the forecast period. This market domination can be owed to a well-developed healthcare sector and a massive patient population residing in the region. Additionally, changing lifestyle and an increasing healthcare expenditure have also contributed to the ascension of the regional osteoarthritis market. In 2015, a report by the Centre for Disease Control and Prevention, 17.8% of US’s total GDP accounted for the country’s healthcare expenditure, which came to USD 3.2 trillion.
Europe, on the other hand is anticipated to follow the Americas and owe for the second largest osteoarthritis market during the forecast period. Such market growth can be attributed to the rising availability of funds for research and a huge patient population for osteoarthritis. Further, increasing healthcare expenditure in the region, along with a well-developed healthcare sector and government support for R&D projects are boosting growth in the regional osteoarthritis market over the review period. Western Europe is anticipated to hold the largest share in the regional osteoarthritis market with Germany, France, and the UK at the forefront. However, Eastern Europe is estimated to grow at a relatively faster rate owing to expansion opportunities for various market players.
Asia Pacific is anticipated to grow at the fastest rate during the forecast period, owing to the presence of a massive patient population and the presence of significant developing countries such as China and India. Further, humongous growth opportunities for various international and regional market players are expected to drive the market.
Browse Complete Report @ https://www.marketresearchfuture.com/reports/osteoarthritis-market-1609
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Statistical Report, Continuous-Feed Research (CFR), and Market Research & Consulting Services.
OverviewThe rise in the number of cases that are being diagnosed with osteoarthritis has risen significantly in the past few years.
Increased investment from investors and market players is anticipated to unlock the growth potential of the marketRequest Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/1609SegmentationThe global osteoarthritis market has been segmented based on type, diagnosis, treatment, and end users.
The imaging segment, is sub-segmented into X-rays, magnetic resonance imaging (MRI), and others.
By end users, the osteoarthritis segment has been hospitals & clinics, medical institutes, research organization, and others.Industry Segments The osteoarthritis market globally is segmented on the basis of diagnosis, type, treatment, and end users.
The presence of a well-developed healthcare sector and the vast patient population suffering from osteoarthritis is a major driving force behind the growth of the regional market.
Western Europe holds a significant share of the regional market, which gets most of the contributions from Germany, France, and the UK.
Osteoarthritis Market Analysis, By Type (Hip Osteoarthritis, Spinal Osteoarthritis) By Diagnosis (Imaging, Joint Fluid Analysis) By Treatment (Medication, Surgery, Therapy) By End Users (Hospitals, Medical Institutes) - Global Forecast till 2023The Global Osteoarthritis Market Analysis shows market is touted to register a CAGR of 6.8% during the forecast period (2017-2023).The surge in the global osteoarthritis market is mainly due to the growing geriatric population, surging demand for minimally invasive surgical procedures, and high prevalence of osteoarthritis across the globe.
It is considered one of the most common joint disease, generally found in people of more than 65 years.
According to the WHO, osteoarthritis is considered one of the ten most disabling diseases, especially in the developed economies.Increased demand for minimally invasive surgical procedures in order to treat osteoarthritis is the primary factor triggering the demand from the osteoarthritis market.
For instance, MAKOplasty is a minimally invasive knee surgery, which helps to relieve pain caused by osteoarthritis.
Government support for funding and ongoing research and development are further creating new growth opportunities for the market.On the contrary, low per capita income, especially in the developing economies, coupled with the side effects associated with the treatment procedures are likely to restrict the market growth in the coming years.Osteoarthritis Market Competitive DashboardThe top players operating in the osteoarthritis market include Novartis AG (Europe), Abbott.
(U.S.), Eli Lilly and Company.
Global Vaccine Conjugates Market OverviewConjugate vaccines are developed through a covalent bond between a weak antigen and a strong antigen.
The global vaccine conjugates market is anticipated to register a 14.5% CAGR over the forecast period of 2018-2027.
For instance, in July 2018, a Chinese vaccine manufacturer was found guilty of fabricating its manufacturing records and faced legal consequences.
On the basis of disease indication, the vaccine conjugates market is segmented into influenza, DTP, pneumococcal, and meningococcal.
Detailed Regional AnalysisThe global vaccine conjugates market is segmented into the regions of the Americas, Europe, Asia Pacific, and the Middle East and Africa.
Asia Pacific is anticipated to grow at a steady rate for vaccine conjugates during the forecast period.
BRAF is a kinase enzyme that helps control cell growth and signaling.
Clinical trials are also being severely affected with disruptions in both new enrollment and in keeping existing patients on therapies.
According to the clinicaltrial.gov, as of April 2020, there were more than 2,850 trials and approximately 900,000 patients enrolled at trial sites in regions that were in partial or complete lockdown due to COVID-19 restrictions.
The R labs are operating at below 50% of normal capacity.The BRAF kinase inhibitors market is estimated to be valued at US$ 924.8 million in 2020 and is expected to exhibit a CAGR of 8.6% during the forecast period (2020-2027).Get PDF Brochure Of This Research Report @https://www.coherentmarketinsights.com/insight/request-pdf/4240The robust pipeline for treatment of metastatic cancers and increasing prevalence of cancer are expected to boost growth of the BRAF kinase inhibitors marketSeveral companies have ongoing clinical trials of BRAF kinase inhibitors drugs.
The robust pipeline of BRAF kinase inhibitor drugs is expected to significantly drive growth of the global BRAF kinase inhibitors market in the near future.
For instance, in June 2020, BeiGene, Ltd., a commercial-stage biotechnology company and SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced the presentation of preclinical data and provided a program update on their ongoing Phase 1b/2 study evaluating the combination of BeiGene’s investigational RAF dimer inhibitor, lifirafenib, with SpringWorks’ investigational MEK inhibitor, mirdametinib, in patients with advanced or refractory solid tumors harboring mutations in the MAPK pathway, including those with RAS mutations.Furthermore, BRAF kinase inhibitors market is expected to witness high growth over the forecast period, owing to increasing incidence and prevalence of metastatic cancer.
The increasing prevalent population of Hemophilia A and the rise in demand of the prophylactics treatments in developed markets will have a great impact on this market.
According to the US Centers for Disease Control and Prevention, hemophilia A occurs in 1 in 5,000 live male births.
Hemophilia A is about four times as common as hemophilia B.
Approximately 75% of people with hemophilia around the world still receive inadequate treatment or have no access to treatment.
The major players with drugs in Phase III are Alnylam Pharmaceuticals, Sanofi (Genzyme), BioMarin Pharmaceutical, Hoffmann-La Roche, Sinocelltech Ltd., Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd, Octapharma, LFB USA, Inc., Novo Nordisk A/S, Pfizer and others.
Polaris Market Research expects that with the expected launch of the promising treatments, the market is expected to expand in Hemophilia A segment.
The increasing prevalent population of Hemophilia A and the rise in demand of the prophylactics treatments in developed markets will have a great impact on this market.
According to the US Centers for Disease Control and Prevention, hemophilia A occurs in 1 in 5,000 live male births.
Hemophilia A is about four times as common as hemophilia B.
Approximately 75% of people with hemophilia around the world still receive inadequate treatment or have no access to treatment.
The major players with drugs in Phase III are Alnylam Pharmaceuticals, Sanofi (Genzyme), BioMarin Pharmaceutical, Hoffmann-La Roche, Sinocelltech Ltd., Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd, Octapharma, LFB USA, Inc., Novo Nordisk A/S, Pfizer and others.
Polaris Market Research expects that with the expected launch of the promising treatments, the market is expected to expand in Hemophilia A segment.
